These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

363 related items for PubMed ID: 15613453

  • 1. Insulin-like growth factor-I receptor signalling and acquired resistance to gefitinib (ZD1839; Iressa) in human breast and prostate cancer cells.
    Jones HE, Goddard L, Gee JM, Hiscox S, Rubini M, Barrow D, Knowlden JM, Williams S, Wakeling AE, Nicholson RI.
    Endocr Relat Cancer; 2004 Dec; 11(4):793-814. PubMed ID: 15613453
    [Abstract] [Full Text] [Related]

  • 2. Insulin receptor substrate-1 involvement in epidermal growth factor receptor and insulin-like growth factor receptor signalling: implication for Gefitinib ('Iressa') response and resistance.
    Knowlden JM, Jones HE, Barrow D, Gee JM, Nicholson RI, Hutcheson IR.
    Breast Cancer Res Treat; 2008 Sep; 111(1):79-91. PubMed ID: 17902048
    [Abstract] [Full Text] [Related]

  • 3. Insulin-like growth factor-I receptor signaling in tamoxifen-resistant breast cancer: a supporting role to the epidermal growth factor receptor.
    Knowlden JM, Hutcheson IR, Barrow D, Gee JM, Nicholson RI.
    Endocrinology; 2005 Nov; 146(11):4609-18. PubMed ID: 16037379
    [Abstract] [Full Text] [Related]

  • 4. Insulin-like growth factor-1 receptor inhibition induces a resistance mechanism via the epidermal growth factor receptor/HER3/AKT signaling pathway: rational basis for cotargeting insulin-like growth factor-1 receptor and epidermal growth factor receptor in hepatocellular carcinoma.
    Desbois-Mouthon C, Baron A, Blivet-Van Eggelpoël MJ, Fartoux L, Venot C, Bladt F, Housset C, Rosmorduc O.
    Clin Cancer Res; 2009 Sep 01; 15(17):5445-56. PubMed ID: 19706799
    [Abstract] [Full Text] [Related]

  • 5. An update of the mechanisms of resistance to EGFR-tyrosine kinase inhibitors in breast cancer: Gefitinib (Iressa) -induced changes in the expression and nucleo-cytoplasmic trafficking of HER-ligands (Review).
    Ferrer-Soler L, Vazquez-Martin A, Brunet J, Menendez JA, De Llorens R, Colomer R.
    Int J Mol Med; 2007 Jul 01; 20(1):3-10. PubMed ID: 17549382
    [Abstract] [Full Text] [Related]

  • 6. Increased constitutive activity of PKB/Akt in tamoxifen resistant breast cancer MCF-7 cells.
    Jordan NJ, Gee JM, Barrow D, Wakeling AE, Nicholson RI.
    Breast Cancer Res Treat; 2004 Sep 01; 87(2):167-80. PubMed ID: 15377841
    [Abstract] [Full Text] [Related]

  • 7. Impact of IGF-1R/EGFR cross-talks on hepatoma cell sensitivity to gefitinib.
    Desbois-Mouthon C, Cacheux W, Blivet-Van Eggelpoël MJ, Barbu V, Fartoux L, Poupon R, Housset C, Rosmorduc O.
    Int J Cancer; 2006 Dec 01; 119(11):2557-66. PubMed ID: 16988945
    [Abstract] [Full Text] [Related]

  • 8. Reduced expression of EI24 confers resistance to gefitinib through IGF-1R signaling in PC9 NSCLC cells.
    Choi JM, Jang JY, Choi YR, Kim HR, Cho BC, Lee HW.
    Lung Cancer; 2015 Nov 01; 90(2):175-81. PubMed ID: 26342551
    [Abstract] [Full Text] [Related]

  • 9. Bidirectional cross talk between ERalpha and EGFR signalling pathways regulates tamoxifen-resistant growth.
    Britton DJ, Hutcheson IR, Knowlden JM, Barrow D, Giles M, McClelland RA, Gee JM, Nicholson RI.
    Breast Cancer Res Treat; 2006 Mar 01; 96(2):131-46. PubMed ID: 16261397
    [Abstract] [Full Text] [Related]

  • 10. Antitumor activity of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib (ZD1839, Iressa) in non-small cell lung cancer cell lines correlates with gene copy number and EGFR mutations but not EGFR protein levels.
    Helfrich BA, Raben D, Varella-Garcia M, Gustafson D, Chan DC, Bemis L, Coldren C, Barón A, Zeng C, Franklin WA, Hirsch FR, Gazdar A, Minna J, Bunn PA.
    Clin Cancer Res; 2006 Dec 01; 12(23):7117-25. PubMed ID: 17145836
    [Abstract] [Full Text] [Related]

  • 11. The antiepidermal growth factor receptor agent gefitinib (ZD1839/Iressa) improves antihormone response and prevents development of resistance in breast cancer in vitro.
    Gee JM, Harper ME, Hutcheson IR, Madden TA, Barrow D, Knowlden JM, McClelland RA, Jordan N, Wakeling AE, Nicholson RI.
    Endocrinology; 2003 Nov 01; 144(11):5105-17. PubMed ID: 12960029
    [Abstract] [Full Text] [Related]

  • 12. The role of MET activation in determining the sensitivity to epidermal growth factor receptor tyrosine kinase inhibitors.
    Rho JK, Choi YJ, Lee JK, Ryoo BY, Na II, Yang SH, Lee SS, Kim CH, Yoo YD, Lee JC.
    Mol Cancer Res; 2009 Oct 01; 7(10):1736-43. PubMed ID: 19808904
    [Abstract] [Full Text] [Related]

  • 13. Implication of the insulin-like growth factor-IR pathway in the resistance of non-small cell lung cancer cells to treatment with gefitinib.
    Morgillo F, Kim WY, Kim ES, Ciardiello F, Hong WK, Lee HY.
    Clin Cancer Res; 2007 May 01; 13(9):2795-803. PubMed ID: 17473213
    [Abstract] [Full Text] [Related]

  • 14. Uncoupling of the epidermal growth factor receptor from downstream signal transduction molecules guides the acquired resistance to gefitinib in prostate cancer cells.
    Festuccia C, Gravina GL, Millimaggi D, Muzi P, Speca S, Ricevuto E, Vicentini C, Bologna M.
    Oncol Rep; 2007 Aug 01; 18(2):503-11. PubMed ID: 17611677
    [Abstract] [Full Text] [Related]

  • 15. Dual epidermal growth factor receptor (EGFR)/insulin-like growth factor-1 receptor (IGF-1R) inhibitor: a novel approach for overcoming resistance in anticancer treatment.
    Tandon R, Kapoor S, Vali S, Senthil V, Nithya D, Venkataramanan R, Sharma A, Talwadkar A, Ray A, Bhatnagar PK, Dastidar SG.
    Eur J Pharmacol; 2011 Sep 30; 667(1-3):56-65. PubMed ID: 21640718
    [Abstract] [Full Text] [Related]

  • 16. Transforming growth factor alpha expression drives constitutive epidermal growth factor receptor pathway activation and sensitivity to gefitinib (Iressa) in human pancreatic cancer cell lines.
    Pino MS, Shrader M, Baker CH, Cognetti F, Xiong HQ, Abbruzzese JL, McConkey DJ.
    Cancer Res; 2006 Apr 01; 66(7):3802-12. PubMed ID: 16585207
    [Abstract] [Full Text] [Related]

  • 17. Growth factor/growth factor receptor loops in autocrine growth regulation of human prostate cancer DU145 cells.
    Ligęza J, Ligęza J, Klein A.
    Acta Biochim Pol; 2011 Apr 01; 58(3):391-6. PubMed ID: 21887406
    [Abstract] [Full Text] [Related]

  • 18. Everolimus synergizes with gefitinib in non-small-cell lung cancer cell lines resistant to epidermal growth factor receptor tyrosine kinase inhibitors.
    Dong S, Zhang XC, Cheng H, Zhu JQ, Chen ZH, Zhang YF, Xie Z, Wu YL.
    Cancer Chemother Pharmacol; 2012 Nov 01; 70(5):707-16. PubMed ID: 22941374
    [Abstract] [Full Text] [Related]

  • 19. Elevated Src activity promotes cellular invasion and motility in tamoxifen resistant breast cancer cells.
    Hiscox S, Morgan L, Green TP, Barrow D, Gee J, Nicholson RI.
    Breast Cancer Res Treat; 2006 Jun 01; 97(3):263-74. PubMed ID: 16333527
    [Abstract] [Full Text] [Related]

  • 20. Inhibition of the AKT/mTOR and erbB pathways by gefitinib, perifosine and analogs of gonadotropin-releasing hormone I and II to overcome tamoxifen resistance in breast cancer cells.
    Block M, Gründker C, Fister S, Kubin J, Wilkens L, Mueller MD, Hemmerlein B, Emons G, Günthert AR.
    Int J Oncol; 2012 Nov 01; 41(5):1845-54. PubMed ID: 22922893
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.